These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11086273)

  • 1. [Pleconaril, a new aniviral drug with activity against picornavirus].
    Reina J; Ballesteros F
    Rev Esp Quimioter; 2000 Sep; 13(3):257-62. PubMed ID: 11086273
    [No Abstract]   [Full Text] [Related]  

  • 2. Pleconaril Sanofi Synthélabo/ViroPharma.
    Billich A
    Curr Opin Investig Drugs; 2000 Nov; 1(3):303-7. PubMed ID: 11249712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibitors of picornavirus replication.
    De Palma AM; Vliegen I; De Clercq E; Neyts J
    Med Res Rev; 2008 Nov; 28(6):823-84. PubMed ID: 18381747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleconaril. A broad spectrum antipicornaviral agent.
    Rogers JM; Diana GD; McKinlay MA
    Adv Exp Med Biol; 1999; 458():69-76. PubMed ID: 10549380
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and efficacy evaluation of pleconaril for treatment of the common cold.
    Fleischer R; Laessig K
    Clin Infect Dis; 2003 Dec; 37(12):1722. PubMed ID: 14689362
    [No Abstract]   [Full Text] [Related]  

  • 6. The need for treatment against human parechoviruses: how, why and when?
    Wildenbeest JG; Harvala H; Pajkrt D; Wolthers KC
    Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1417-29. PubMed ID: 21133666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials.
    Hayden FG; Coats T; Kim K; Hassman HA; Blatter MM; Zhang B; Liu S
    Antivir Ther; 2002 Mar; 7(1):53-65. PubMed ID: 12008788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials.
    Hayden FG; Herrington DT; Coats TL; Kim K; Cooper EC; Villano SA; Liu S; Hudson S; Pevear DC; Collett M; McKinlay M;
    Clin Infect Dis; 2003 Jun; 36(12):1523-32. PubMed ID: 12802751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia.
    van de Ven AA; Douma JW; Rademaker C; van Loon AM; Wensing AM; Boelens JJ; Sanders EA; van Montfrans JM
    Antivir Ther; 2011; 16(4):611-4. PubMed ID: 21685550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3.
    Schmidtke M; Wutzler P; Zieger R; Riabova OB; Makarov VA
    Antiviral Res; 2009 Jan; 81(1):56-63. PubMed ID: 18840470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of picornavirus uncoating as antiviral agents.
    Diana GD; Otto MJ; McKinlay MA
    Pharmacol Ther; 1985; 29(3):287-97. PubMed ID: 3014575
    [No Abstract]   [Full Text] [Related]  

  • 12. [Polio-like myelitis due to Coxsackie-Virus B 3: Course under treatment with pleconaril].
    Utzig N; Friedrich B; Burtzlaff C; Lauffer H
    Klin Padiatr; 2003; 215(5):286-7. PubMed ID: 14520593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral agents against picornaviruses.
    Eggers HJ
    Antiviral Res; 1985; Suppl 1():57-65. PubMed ID: 3002267
    [No Abstract]   [Full Text] [Related]  

  • 14. Discovery and development of antipicornaviral agents.
    McKinlay MA
    Scand J Infect Dis Suppl; 1993; 88():109-15. PubMed ID: 8516662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral treatments reduce severity of diabetes in Ljungan virus-infected CD-1 mice and delay onset in diabetes-prone BB rats.
    Holmberg R; Klitz W; Blixt M; Berggren PO; Juntti-Berggren L; Niklasson B
    Microbiol Immunol; 2009 Oct; 53(10):567-72. PubMed ID: 19780970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pleconaril, a novel antipicornaviral agent.
    Florea NR; Maglio D; Nicolau DP
    Pharmacotherapy; 2003 Mar; 23(3):339-48. PubMed ID: 12627933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment.
    Schmidtke M; Hammerschmidt E; Schüler S; Zell R; Birch-Hirschfeld E; Makarov VA; Riabova OB; Wutzler P
    J Antimicrob Chemother; 2005 Oct; 56(4):648-56. PubMed ID: 16150864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the treatment of rhinovirus infections.
    McKinlay MA
    Curr Opin Pharmacol; 2001 Oct; 1(5):477-81. PubMed ID: 11764773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Picornavirus inhibitors.
    Carrasco L
    Pharmacol Ther; 1994; 64(2):215-90. PubMed ID: 7533301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to pleconaril.
    Ledford RM; Collett MS; Pevear DC
    Antiviral Res; 2005 Dec; 68(3):135-8. PubMed ID: 16199099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.